KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.

A Vanzulli, R Vigorito, C Buonomenna, E Palmerini, V Quagliuolo, J M Broto, A Lopez Pousa, G Grignani, A Brunello, J-Y Blay, R Diaz Beveridge, V Ferraresi, I Lugowska, S Pizzamiglio, P Verderio, V Duroni, V Fontana, D M Donati, E Palassini, G Bianchi, A Bertuzzi, A Buonadonna, S Pasquali, A P Dei Tos, P G Casali, C Morosi, S Stacchiotti, A Gronchi

ESMO Open 10(3) 104299

PMID40056850
PMCIDPMC11930716
DOI10.1016/j.esmoop.2025.104299
发表日期2025-03-08
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: We report the results of the pre-planned secondary analysis of radiologic responses (RRs) of ISG-STS 1001, a randomized trial comparing anthracycline + ifosfamide (AI) versus histology-tailored (HT) neoadjuvant chemotherapy for primary localized high-risk soft-tissue sarcomas of the extremities and trunk wall. PATIENTS AND METHODS: Patients with undifferentiated pleomorphic sarcoma (UPS), leiomyosarcoma (LMS), malignant peripheral nerve sheath tumor, synovial sarcoma or myxoid liposarcoma (MLPS) were randomized, whereas patients with myxofibrosarcoma, pleomorphic liposarcoma, pleomorphic rhabdomyosarcoma or unclassified sarcoma were included in the observational arm (O) and treated with AI. Patients with UPS, LMS or MLPS needing concurrent preoperative radiotherapy were included in O. We evaluated associations between: disease-free survival (DFS)/overall survival (OS) and centrally reviewed RR, assessed with RECIST 1.1 and as percent dimensional variation (D; both dichotomized and continuous); DFS/OS and histology; RR and histology. RESULTS: Four hundred and thirty-five patients were included (287 randomized, 148 observed). The analysis of RRs comprised 236 patients (154 randomized, 82 observed) with measurable disease and available for central review. RECIST best responses were: 28 (11.9%) partial response (PR), 195 (82.6%) stable disease (SD), 13 (5.5%) progressive disease (PD). RECIST significantly correlated with DFS [PD versus PR: hazard ratio (HR) 8.18, 95% confidence interval (CI) 2.96-22.58; SD versus PR: HR 2.96, 95% CI 1.30-6.75] and OS (PD versus PR: HR 12.61, 95% CI 3.40-46.84; SD versus PR: HR 4.24, 95% CI 1.34-13.47). The median value of D was -1.6%. Patients with D >-1.6% had worse clinical outcomes than those with D <-1.6% (DFS: HR 1.73, 95% CI 1.19-2.50; OS: HR 1.86, 95% CI 1.21-2.86). D in continuous scale inversely correlated with DFS (HR 1.53, 95% CI 1.25-1.87) and OS (HR 1.78, 95% CI 1.41-2.25). CONCLUSIONS: These results confirm the prognostic value of RRs as per RECIST and D and demonstrate that any variation in size predicts the proportional efficacy of treatment.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2 Disease-free and overall survival probabilities according to RECIST 1.1. (A) Disease-free survival and (B) overall survival probabilities of RECIST 1.1 ( n = 236). (C) Disease-free survival and (D) overall survival probabilities of dichotomized percent dimensional variation after the third cycle of neoadjuvant chemotherapy ( n = 236). (E) Disease-free survival and (F) overall survival probabilities of different histologies on the overall series of patients with measurable disease ( n = 366). LMS, leiomyosarcoma; MFS, myxofibrosarcoma; MLPS, myxoid liposarcoma; MPNST, malignant peripheral nerve sheath tumor; SYNOV, synovial sarcoma; UPS, undifferentiated pleomorphic sarcoma.

E

Disease-free survival

Figure 2 · Panel E

quality_warning 待 EXE 对齐 预期 8 条 已提取 7 条

Panel E 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 8 条,实际恢复 7 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
F

Overall survival

Figure 2 · Panel F

quality_warning 待 EXE 对齐 预期 8 条 已提取 7 条

Panel F 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 8 条,实际恢复 7 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure2 个面板

Figure 3

Figure 3 Disease-free and overall survival probabilites according to dichotomized percent dimensional variation after the third cycle of neoadjuvant chemotherapy. (A) Disease-free survival and (B) overall survival probabilities of percent dimensional variation after the third cycle of neoadjuvant chemotherapy in continuous scale at median follow-up ( n = 236).

A

Disease-free survival

Figure 3 · Panel A

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall survival

Figure 3 · Panel B

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 CONSORT diagram detailing study design and treatment arms. a Randomized patients: 65/93 in arm A and 63/64 in arm B (1 patient was randomized as UPS, but histological central review concluded for MFS, non-randomizable histology as per study protocol; the patient was excluded from our analyses). AI, anthracycline + ifosfamide; CONSORT, Consolidated Standards of Reporting Trials; HT, histology-tailored chemotherapy; MFS, myxofibrosarcoma; RT, radiotherapy; UPS, undifferentiated pleomorphic sarcoma.
非 KM Figure